Kinase Inhibitor
Showing 1 - 25 of >10,000
Pancreatic Ductal Adenocarcinoma Trial (combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- combination therapy with no MEKi
- +3 more
- (no location specified)
Nov 29, 2022
Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase
Recruiting
- Liver Transplant
- PVHA or TACE
-
Shanghai, Shanghai, ChinaThe value of tumor feeding vessels deprivation combined with tyr
Nov 26, 2022
Liver Tumors Trial in Beijing (Tislelizumab plus tyrosine kinase inhibitor)
Recruiting
- Liver Neoplasms
- Tislelizumab plus tyrosine kinase inhibitor
-
Beijing, Beijing, China302 Hospital
Sep 22, 2023
Cyclin-dependent Kinase Inhibitor 2A on Labor-related Signals
Not yet recruiting
- Preterm Labor
- (no location specified)
May 9, 2023
Breast Cancer Trial in Guangzhou (Take probiotics)
Recruiting
- Breast Cancer
- Take probiotics
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Mar 6, 2023
HRQOL in Locally Advanced Thyroid Carcinoma
Recruiting
- Thyroid Cancer
- +2 more
- Tyrosine kinase inhibitor drugs.
-
Fuzhou, Fujian, ChinaRoad Fuma No.420
Apr 11, 2023
Sjogren's Syndrome Trial run by the National Institute of Dental and Craniofacial Research (NIDCR) (tofacitinib, Placebo)
Recruiting
- Sjogren's Syndrome
- tofacitinib
- Placebo
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Nov 24, 2022
Gastrointestinal Stromal Tumors (GISTs) Trial in Seoul (Imatinib Mesylate)
Completed
- Gastrointestinal Stromal Tumors (GISTs)
- Imatinib Mesylate
-
Seoul, Korea, Republic ofAsan Medical Center
Dec 30, 2022
SCLC, Small Cell Cancer, Advanced Solid Tumor Trial run by the NCI (Lurbinectedin, Berzosertib)
Recruiting
- SCLC
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Multiple Sclerosis Trial run by the National Institute of Neurological Disorders and Stroke (NINDS) (tolebrutinib 60mg,
Active, not recruiting
- Multiple Sclerosis
- tolebrutinib 60mg
- tolebrutinib 120mg
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma Trial in Saint Louis (device, drug, procedure)
Recruiting
- Pancreas Cancer
- +2 more
- MR-guided stereotactic body radiation therapy
- +3 more
-
Saint Louis, MissouriWashington University School of Medicine
Jan 29, 2023
Kinase Inhibitor Targeted Therapies
Not yet recruiting
- Blood Concentrations of Nine Anti-cancer Drugs : Axitinib, Olaparib, regorafénib, Cabozantinib, Niraparib, Talazoparib, Palbociclib, Abemaciclib, Tucatinib
- Measurement of drug concentrations
-
Rennes, France
- +2 more
Nov 7, 2022
Acute Lymphoblastic Leukemia Trial in Ann Arbor (Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy)
Recruiting
- Acute Lymphoblastic Leukemia
- Dasatinib
- +3 more
-
Ann Arbor, MichiganUniversity of Michigan Rogel Cancer Center
Nov 28, 2022
Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia
Not yet recruiting
- Tyrosine Kinase Inhibitor
- +2 more
-
Taipei, TaiwanNational Taiwan University Hospital
Feb 17, 2022
CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)
Recruiting
- CML
- Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
-
Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, ArgentinaFUNDALEU
Jun 29, 2023
Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive Trial in New York (Blinatumomab, dasatinib, dexamethasone)
Recruiting
- Acute Lymphoblastic Leukemia
- Philadelphia Chromosome-Positive
- Blinatumomab
- +3 more
-
New York, New York
- +1 more
Nov 10, 2022
High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Surufatinib, Sintilimab, Radiotherapy)
Recruiting
- High-Risk Localized Soft Tissue Sarcoma
- Surufatinib
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 20, 2023
Janus Kinase Inhibitor Therapy in Ulcerative Colitis
Terminated
- Ulcerative Colitis
- Janus Kinase Inhibitor
-
Amsterdam, North Halland, NetherlandsAmsterdam Medical Center, IBD Center
Dec 14, 2021
Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma Trial in Beijing (multi-kinase inhibitors in
Not yet recruiting
- Liver Transplant; Complications
- +3 more
- multi-kinase inhibitors in combination with bevacizumab
-
Beijing, Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical Colle
Sep 11, 2023
Metabolic Alternation and Clinicohematological Characteristic in
Not yet recruiting
- CML, Chronic Phase
- Tyrosine kinase inhibitor
- (no location specified)
Nov 6, 2023
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Australia, Poland (TG-1701, Umbralisib, Ublituximab)
Active, not recruiting
- Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- TG-1701
- +2 more
-
East Melbourne, Victoria, Australia
- +7 more
Jan 20, 2023
Cancer Trial in Boston (CYC065)
Active, not recruiting
- Cancer
-
Boston, MassachusettsDana-Farber Cancer Institute
Apr 22, 2022
Cancer Trial in Changsha (Protein Kinase Inhibitor)
Recruiting
- Cancer
- Protein Kinase Inhibitor
-
Changsha, Hunan, ChinaCentral South University
Jun 23, 2022
